Allopurinol Combination Study (RDEA594-203)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01001338|
Recruitment Status : Completed
First Posted : October 26, 2009
Last Update Posted : January 24, 2017
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Gout||Drug: RDEA594 Drug: Placebo Drug: Allopurinol||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||227 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients With an Inadequate Hypouricemic Response With Standard Doses of Allopurinol|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||August 2016|
Experimental: RDEA594 200 mg qd
RDEA594 200 mg qd plus allopurinol qd
Uricosuric agent for the treatment of gout.
Experimental: RDEA594 200 mg, 400 mg qd
RDEA594 200 mg then 400 mg qd plus allopurinol qd.
Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015.
Uricosuric agent for the treatment of gout.
Placebo Comparator: Matching Placebo
RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.
Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015.
Experimental: RDEA594 600 mg qd
RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd
Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015.
Uricosuric agent for the treatment of gout.
- To compare the percent reduction from baseline in serum urate levels following 4 wks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response. [ Time Frame: 28 days ]
- To evaluate the proportion of subjects whose sUA levels are < 6.0 mg/dL, < 5.0 mg/dL and < 4.0 mg/dL at each study visit by treatment group in all subjects and in subjects who have an sUA ≥6 mg/dL at the baseline visit. [ Time Frame: 28 days and through extension ]
- To evaluate the absolute and percent reduction from baseline in sUA levels at each visit. [ Time Frame: 28 days and through extension ]
- To evaluate the percentage change in 24-hour urine urate level (excretion) from baseline to Day 28. [ Time Frame: 28 days and through extension ]
- To evaluate the incidence of gout flares. [ Time Frame: 28 days and through extension ]
- To evaluate the safety and tolerability of RDEA594 in combination with allopurinol in subjects with gout. [ Time Frame: 28 days and through extension ]
- To compare the multiple-dose pharmacokinetics (PK) of allopurinol and oxypurinol in the absence versus presence of RDEA594 co-administration. [ Time Frame: 28 days ]
- To evaluate the proportion of subjects whose sUA level decreases to or is maintained at <6.0 mg/dL and <5.0 mg/dL in the Double-Blind and Open-Label Extension Period. [ Time Frame: 3 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or a post-menopausal or surgically sterile female.
- 18 - 80 years of age.
- Has been taking allopurinol as the sole urate lowering therapy for hyperuricemia for at least 6 weeks at a dose between 200 mg and 600 mg per day without an adequate response.
- Has a sUA level ≥ 6 mg/dL at screening.
- Meets criteria for the diagnosis of gout as per the American Rheumatism Association (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.
- Willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed).
- Subjects entering the optional Extension Period must have completed 28 days of dosing in the Double-Blind Treatment Period and the Day 42 Visit in the Follow-up Period within 4 months and must not have experienced any serious adverse events considered possibly related to study drug.
- Subjects entering the optional Open-Label Extension Period must continue to be compliant with the protocol through Week 44 of the Double-Blind Extension Period and must not have experienced any serious adverse events considered possibly related to study drug.
- Consumes more than 14 drinks of alcohol per week (e.g., 1 drink = 5 oz [150 ml] of wine, 12 oz [360 ml] of beer, or 1.5 oz [45 ml] of hard liquor).
- History or suspicion of drug abuse.
- History of documented or suspected kidney stones.
- Has rheumatoid arthritis or other autoimmune disease requiring treatment.
- Documented or suspicion of HIV infection.
- Positive serology to HCV antibodies (Abs), and/or hepatitis B surface antigen (HBsAg).
- History of malignancy within 5 years prior to the first dose of study medication, other than non-melanomatous skin cancer or cervical dysplasia.
- History of cardiac abnormalities, including abnormal and clinically relevant ECG changes
- Any condition predisposing to QT prolongation including pathological Q-wave (defined as Q-wave >40 msec or depth > 0.4-0.5 mV).
- Any use of concomitant medications that prolong the QT/QTc interval within the 14 days prior to Baseline (Day 1).
- QT interval corrected for heart rate according to Fridericia (QTcF) > 450 msec at Screening or pre-dose at Baseline (Day 1).
- Uncontrolled hypertension (above 150/95).
- Inadequate renal function [serum creatinine >1.5 mg/dL or creatinine clearance < 60 mL/min (by Cockroft-Gault formula)].
- Hemoglobin < 10 g/dL (males) or < 9 g/dL (females).
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN).
- Gamma glutamyl transferase (GGT) > 3 x ULN.
- Active peptic ulcer disease requiring treatment.
- History of xanthinuria, active liver disease, or hepatic dysfunction.
- Requires therapy with any other urate-lowering medication, other than the study medications.
- Requires long-term use of salicylates; diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole; or trimethoprim.
- Taking medications known as enzyme inducers (see section 3.7 for listing).
- Reports receiving a strong or moderate inhibitor of CYP3A4 or a P-gp inhibitor within 1 month prior to study drug dosing, due to potential interactions with colchicine.
- Acute gout flare (exclusive of chronic synovitis/ arthritis) during the Screening-Period that has not resolved one week prior to the Baseline Visit (Day 0).
- Pregnant or breast feeding.
- Has received an investigational medication within 4 weeks prior to the screening visit for this study.
- Previously participated in a clinical study involving RDEA806 or RDEA594.
- Known hypersensitivity or allergy to RDEA594, allopurinol or colchicine or any components in their formulations.
- Body mass index (BMI) >48 kg/m2.
- Taking greater than 1000 mg/day of Vitamin C.
- Any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
- Inadequate renal function after completing the Double-Blind Treatment period prior to entering Double-Blind Extension Period.
- Requiring treatment with prohibited medications noted in exclusion criteria numbers 20-23 after completing the Double-Blind Treatment Period prior to entering the Extension Period.
- Clinically relevant medical event as determined by the investigator in consultation with medical monitor prior to entering the Extension Period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01001338
|United States, Arizona|
|Phoenix, Arizona, United States, 85050|
|United States, California|
|La Jolla, California, United States, 92037|
|Los Angeles, California, United States, 90017|
|Stanford, California, United States, 94305|
|United States, Florida|
|Boca Raton, Florida, United States, 33432|
|DeLand, Florida, United States, 32720|
|Fort Lauderdale, Florida, United States, 33334|
|Jupiter, Florida, United States, 33458|
|United States, Idaho|
|Meridan, Idaho, United States, 83642|
|United States, Kentucky|
|Lexington, Kentucky, United States, 40504|
|United States, Maryland|
|Wheaton, Maryland, United States, 20902|
|United States, Nevada|
|Las Vegas, Nevada, United States, 89183|
|Reno, Nevada, United States, 89502|
|United States, North Carolina|
|Harrisburg, North Carolina, United States, 28075|
|United States, Ohio|
|Cincinnati, Ohio, United States, 45242|
|Cleveland, Ohio, United States, 44122|
|Mayfield Village, Ohio, United States, 44143|
|United States, South Carolina|
|Durham, South Carolina, United States, 27710|
|Rock Hill, South Carolina, United States, 29732|
|United States, Tennessee|
|Germantown, Tennessee, United States, 38138|
|Jackson, Tennessee, United States, 38305|
|United States, Texas|
|Dallas, Texas, United States, 75231|
|San Antonio, Texas, United States, 78221|
|United States, Utah|
|West Jordan, Utah, United States, 84088|
|United States, Virginia|
|Chesapeake, Virginia, United States, 23320|
|Canada, British Columbia|
|Coquitlam, British Columbia, Canada, V3K 3P4|
|Kelowna, British Columbia, Canada, V1Y8E7|
|Canada, Newfoundland and Labrador|
|St. John's, Newfoundland and Labrador, Canada, A1A 3R5|
|Thornhill, Ontario, Canada, L4J 6W6|
|Toronto, Ontario, Canada, M9W 4L6|
|Mirabel, Quebec, Canada, J7J 2K8|
|Bydgoszcz, Poland, 85-168|
|Elblag, Poland, 82-300|
|Lublin, Poland, 20-607|
|Poznan, Poland, 60-773|
|Radom, Poland, 26-610|
|Torun, Poland, 87-100|
|Bilbao, Spain, 48903|
|Donetsk, Ukraine, 83045|
|Kharkiv, Ukraine, 61176|
|Kyiv, Ukraine, 01610|
|Kyiv, Ukraine, 02125|
|Vinnytsya, Ukraine, 21081|
|Blackpool, Lancashire, United Kingdom, FY4 3AD|
|Study Director:||Nihar Bhakta, MD||Ardea Biosciences, Inc.|
|Responsible Party:||Ardea Biosciences, Inc.|
|Other Study ID Numbers:||
|First Posted:||October 26, 2009 Key Record Dates|
|Last Update Posted:||January 24, 2017|
|Last Verified:||January 2017|
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Molecular Mechanisms of Pharmacological Action
Free Radical Scavengers
Physiological Effects of Drugs